CDF-Adrenal™: A Composite Diagnostic Fingerprint for Adrenal Insufficiency
- 5 days ago
- 17 min read
Updated: 2 days ago
A Dynamic Systems Framework for Early Detection, Crisis Prevention, and Adaptive Stability Assessment
By Cynthia Adinig
Introduction: Why Adrenal Insufficiency Is Still Being Missed
Adrenal insufficiency is widely recognized as a potentially life-threatening endocrine disorder, yet early recognition remains inconsistent and frequently delayed. Patients often present with fatigue, orthostatic symptoms, nausea, cognitive dysfunction, weight loss, salt craving, hypotension, electrolyte abnormalities, or stress intolerance long before overt adrenal crisis occurs. Because these manifestations emerge across time and systems rather than as a single defining event, diagnosis is frequently fragmented across specialties and clinical encounters (Bornstein et al., 2016; NICE, 2024).
In practice, adrenal insufficiency behaves as a dynamic failure of physiologic stress buffering rather than a static hormone deficiency alone. Cortisol and mineralocorticoid signaling regulate vascular tone, electrolyte balance, glucose metabolism, inflammatory control, autonomic adaptation, and survival during physiologic stress. When this adaptive system becomes impaired, instability often appears across multiple organ systems before crisis is formally recognized (Charmandari et al., 2014; Bancos et al., 2015).
Patients are frequently evaluated in isolated clinical silos. Orthostatic symptoms may be routed to cardiology, gastrointestinal symptoms to gastroenterology, fatigue dismissed as nonspecific, and neurocognitive symptoms treated separately. The result is not necessarily a lack of disease, but a failure to recognize the broader adaptive failure pattern underlying the presentation. Delays become especially dangerous because adrenal insufficiency may remain partially compensated until infection, surgery, vomiting, dehydration, medication interruption, or physiologic stress precipitates adrenal crisis (Hahner et al., 2015; Rushworth et al., 2019).
This fragmentation is compounded by the realities of real-world disease management. Patients with adrenal insufficiency frequently perform substantial adaptive labor outside formal healthcare systems through stress dosing, crisis avoidance strategies, environmental control, medication planning, and constant monitoring of physiologic changes. Conventional frameworks largely capture only overt collapse requiring emergency intervention while overlooking the prolonged instability and decision-making burden that often precede crisis. CDF-Adrenal™ was developed to address this gap by reframing adrenal insufficiency as a dynamic systems-pattern disorder rather than a purely threshold-based endocrine condition. The framework translates distributed physiologic signals into a structured, multi-domain diagnostic and stability model capable of supporting earlier recognition, more consistent interpretation, crisis prevention, and future adaptive monitoring systems.
What Is CDF-Adrenal™?
CDF-Adrenal™ is a composite diagnostic framework that evaluates adrenal insufficiency through cross-system pattern recognition rather than reliance on isolated cortisol thresholds or late-stage crisis presentation alone. Instead of treating adrenal insufficiency as a binary endocrine state identified only after substantial physiologic decompensation, the framework evaluates how strongly a patient’s presentation aligns with a broader adrenal instability pattern across multiple interacting domains.
The model integrates endocrine signaling, electrolyte balance, autonomic compensation, crisis vulnerability, medication continuity, environmental stress exposure, and structural barriers to care into a unified diagnostic architecture. This reflects the known heterogeneity of adrenal insufficiency, where symptom severity, compensation capacity, and crisis vulnerability vary substantially across individuals and over time (Bornstein et al., 2016; Bancos et al., 2015).
Importantly, CDF-Adrenal™ does not replace existing endocrinology guidelines or established testing protocols. Rather, it operationalizes them within a systems-based framework that reflects how adrenal instability presents in real-world patients. The model is designed to complement standard endocrine evaluation by improving contextual interpretation, reducing fragmentation, and identifying instability patterns earlier and more consistently.
A central principle of the framework is that adrenal insufficiency cannot be fully understood through cortisol levels alone. Cortisol interpretation is highly dependent on assay type, specimen methodology, circadian timing, concurrent illness, medication exposure, and physiologic state. Emerging literature demonstrates substantial variability across immunoassays, assay generations, salivary testing methods, and LC-MS/MS platforms, limiting the portability of universal threshold assumptions (Miller et al., 2013; Noel et al., 2022; Antonelli et al., 2023).
CDF-Adrenal™ therefore treats assay context as a first-class diagnostic variable rather than an afterthought. Every cortisol interpretation within the framework incorporates assay-aware metadata, including specimen type, platform methodology, and threshold applicability. This reduces false certainty and supports safer interpretation across heterogeneous testing environments.
The framework also recognizes that adrenal insufficiency exists within broader systems of adaptive strain. Environmental heat exposure, infection burden, disrupted medication access, insurance instability, caregiver burden, travel, psychological stress, and healthcare fragmentation can all function as physiologic risk multipliers that shape crisis probability and disease stability over time. Within CDF-Adrenal™, these contextual variables are not treated as secondary social details. They are incorporated directly into disease interpretation because they materially alter physiologic reserve, crisis vulnerability, and patient outcomes.
The Core Problem: Adrenal Insufficiency as a Pattern Recognition Failure
Adrenal insufficiency is frequently delayed in diagnosis not because it lacks recognizable symptoms, but because those symptoms are temporally distributed, systemically fragmented, and often nonspecific in isolation. Fatigue, dizziness, nausea, cognitive dysfunction, orthostatic intolerance, abdominal pain, weight loss, and weakness may each be attributed to separate conditions before the underlying endocrine pattern is recognized (Charmandari et al., 2014).
Patients often present with:
persistent fatigue and reduced stress tolerance
orthostatic dizziness or hypotension
gastrointestinal symptoms including nausea, vomiting, and abdominal pain
salt craving and fluid instability
cognitive dysfunction or “brain fog”
weight loss and appetite disruption
electrolyte abnormalities including hyponatremia and hyperkalemia
recurrent collapse during physiologic stress events
These manifestations frequently evolve gradually rather than simultaneously. Some patients remain partially compensated for prolonged periods before acute physiologic stress unmasks instability. As a result, adrenal insufficiency is often recognized only after severe deterioration or adrenal crisis has already occurred (Rushworth et al., 2019).
At the biologic level, adrenal insufficiency reflects impaired physiologic buffering capacity. Cortisol functions not simply as a hormone, but as a central regulator of inflammation, vascular responsiveness, glucose availability, electrolyte balance, and adaptive survival during stress. When cortisol signaling becomes insufficient, the body progressively loses the ability to maintain stable physiologic compensation under changing demands. This instability is dynamic rather than static. Patients may fluctuate between relative stability, increased demand states, partial decompensation, absorption failure risk, and overt crisis depending on infection exposure, medication continuity, sleep disruption, environmental stressors, or concurrent illness burden.
Conventional diagnostic systems struggle to capture this variability because they rely heavily on static interpretation models. Morning cortisol thresholds are frequently treated as definitive despite substantial assay variability, circadian fluctuation, medication suppression effects, and contextual instability. NICE guidance itself explicitly notes that cortisol interpretation thresholds are assay-dependent and may require local adaptation depending on testing methodology (NICE, 2024).
Research evaluating cortisol assays further demonstrates that measurement variability is not trivial. Immunoassays may differ substantially from LC-MS/MS methods due to cross-reactivity, calibration differences, and matrix interference, particularly in salivary testing (Miller et al., 2013; Antonelli et al., 2023). Noel et al. (2022) similarly demonstrated that diagnostic cortisol thresholds shift significantly across assay generations, reinforcing the need for assay aware interpretation frameworks. Without structured systems-based interpretation, patients may receive fragmented explanations for distributed physiologic signals while the broader endocrine instability pattern remains unrecognized. CDF-Adrenal™ addresses this by translating distributed signals into a unified diagnostic structure capable of integrating biologic, contextual, and operational risk into a composite adrenal instability fingerprint.
CDF-Adrenal™ Domain Architecture
The CDF-Adrenal™ framework organizes adrenal insufficiency into a structured multi-domain architecture adapted from CYNAERA’s broader diagnostic modeling systems. Each domain captures a distinct layer of physiologic instability, ranging from cortisol signaling and electrolyte regulation to crisis readiness and structural healthcare vulnerability. This architecture reflects adrenal insufficiency as a dynamic systems disorder rather than a static endocrine threshold condition. The framework incorporates the following weighted domains:
Core Domain Structure
Domain 1. Cortisol Sufficiency and Circadian Signaling (18%)
Captures morning cortisol adequacy, circadian rhythm integrity, physiologic buffering capacity, and endocrine stress-response signaling. Cortisol production follows tightly regulated circadian dynamics, and disruption of these patterns contributes significantly to instability and impaired adaptive capacity (Bornstein et al., 2016).
Domain 2. Electrolyte and Mineralocorticoid Stability (14%)
Evaluates sodium regulation, potassium balance, renin activity, aldosterone-related instability, salt craving, and fluid compensation patterns. Electrolyte disruption frequently represents one of the earliest measurable physiologic indicators of adrenal dysfunction (Bancos et al., 2015).
Domain 3. Orthostatic and Autonomic Compensation (14%)
Measures orthostatic hypotension, dizziness, syncope risk, autonomic instability, stress intolerance, and vascular compensation failure. Loss of cortisol and mineralocorticoid support impairs vascular responsiveness and physiologic adaptation to positional and systemic stressors.
Domain 4. ACTH and Endocrine Pattern Recognition (12%)
Captures ACTH signaling relationships, pituitary-hypothalamic involvement, steroid suppression patterns, and broader endocrine-axis dysfunction. This domain supports differentiation between primary, secondary, and tertiary adrenal insufficiency states.
Domain 5. Crisis Vulnerability and Physiologic Reserve (16%)
Evaluates prior adrenal crises, near-miss events, vomiting and absorption failure risk, infection vulnerability, recurrent decompensation patterns, and overall physiologic reserve capacity. This domain reflects the reality that crisis risk often accumulates before formal emergency presentation.
Domain 6. Medication Stability and Access Continuity (10%)
Assesses corticosteroid access reliability, refill continuity, insurance disruption, emergency medication availability, adherence barriers, and treatment interruption risk. Medication continuity functions as a core physiologic stabilizer in adrenal insufficiency management.
Domain 7. Environmental, Structural, and Adaptive Burden (16%)
Captures external stressors and systemic modifiers including heat exposure, infection burden, travel, caregiving demands, healthcare fragmentation, diagnostic delay, environmental instability, and adaptive labor required to prevent physiologic collapse. These domains reflect a core CYNAERA principle: adrenal insufficiency is not solely a biochemical deficiency state, but a distributed adaptive systems disorder shaped by physiologic signaling, environmental demand, structural access, and real-world crisis management burden.
The CDF-Adrenal™ Formula
For a given patient p, the CDF-Adrenal™ score is calculated across domains:
CDF-Adrenal(p) = Σ [ wₖ × Dₖ(p) × Rₖ × Sₖ × Uₖ(p) × Mₖ(p) ]
Where:
Dₖ(p) = Domain signal, scored from 0 to 1
Rₖ = Reliability
Sₖ = Specificity
Uₖ(p) = Data usability
Mₖ(p) = Modifier, including assay context, environmental stressors, medication continuity, physiologic stress load, comorbidities, and structural barriers
wₖ = Domain weight
Each domain produces a Domain Trust Score reflecting both biological signal strength and contextual reliability.
Domain Trust Calculation
For each domain:
Tₖ = Dₖ × Rₖ × Sₖ × Uₖ × Mₖ
Weighted contribution:
Cₖ = wₖ × Tₖ
Final composite score:
CDF-Adrenal(p) = Σ Cₖ
Interpretation Bands
≥ 0.75 → High-confidence adrenal insufficiency pattern
Strong multi-domain alignment with adrenal instability requiring endocrine evaluation, crisis-risk assessment, and stabilization planning.
0.50–0.74 → Probable adrenal insufficiency pattern
Moderate-to-high adrenal instability signal requiring further endocrine testing, monitoring, and protective management consideration.
0.30–0.49 → Early or partial adrenal instability phenotype
Distributed physiologic signals suggestive of impaired stress buffering or evolving adrenal dysfunction that warrant monitoring and longitudinal reassessment.
< 0.30 → Low likelihood as primary driver
Limited adrenal-pattern alignment based on current available data.
Diagnostic Fingerprint Calculation: Worked Example
Below is an illustrative example demonstrating how CDF-Adrenal™ may be applied in practice.
Patient Profile
Female, age 38
Persistent fatigue and orthostatic dizziness
Salt craving and intermittent nausea
Low-normal morning cortisol
Hyponatremia with borderline elevated potassium
Repeated worsening during infections and heat exposure
History of prolonged corticosteroid use
Vomiting episodes causing medication absorption concerns
This presentation reflects a partially compensated adrenal instability pattern with elevated crisis vulnerability despite incomplete endocrine confirmation.
Step 1: Domain Scoring
Domain | D_k | R_k | S_k | U_k | M_k | T_k | w_k | C_k |
Cortisol Sufficiency and Circadian Signaling | 0.74 | 0.86 | 0.84 | 0.88 | 0.92 | 0.414 | 0.18 | 0.0745 |
Electrolyte and Mineralocorticoid Stability | 0.68 | 0.82 | 0.78 | 0.84 | 0.90 | 0.328 | 0.14 | 0.0459 |
Orthostatic and Autonomic Compensation | 0.72 | 0.80 | 0.72 | 0.82 | 0.88 | 0.298 | 0.14 | 0.0417 |
ACTH and Endocrine Pattern Recognition | 0.55 | 0.78 | 0.74 | 0.76 | 0.86 | 0.211 | 0.12 | 0.0253 |
Crisis Vulnerability and Physiologic Reserve | 0.82 | 0.88 | 0.84 | 0.90 | 0.94 | 0.509 | 0.16 | 0.0814 |
Medication Stability and Access Continuity | 0.60 | 0.76 | 0.68 | 0.82 | 0.90 | 0.229 | 0.10 | 0.0229 |
Environmental, Structural, and Adaptive Burden | 0.78 | 0.84 | 0.74 | 0.88 | 0.94 | 0.403 | 0.16 | 0.0645 |
Step 2: Final Score Calculation
CDFAdrenal(p)=∑CkCDF_{Adrenal}(p)=\sum C_kCDFAdrenal(p)=∑Ck
= 0.0745
0.0459
0.0417
0.0253
0.0814
0.0229
0.0645
Final Score: 0.3562
Interpretation
A score of 0.36 indicates:
Early to moderate adrenal instability pattern with meaningful physiologic stress buffering impairment requiring monitoring, endocrine reassessment, and crisis risk mitigation.
While the patient may not yet meet definitive high confidence adrenal insufficiency classification, the framework identifies distributed instability signals concentrated in:
cortisol sufficiency and circadian disruption
electrolyte instability
orthostatic compensation failure
crisis vulnerability
environmental and adaptive burden
The model highlights that instability exists before full decompensation and may worsen substantially during infection, heat exposure, gastrointestinal illness, or medication interruption.
Clinical Implications
Repeat endocrine evaluation and assay aware cortisol interpretation
Assess ACTH, renin, aldosterone, and medication suppression history
Monitor orthostatic symptoms and stress triggered deterioration patterns
Develop individualized stress dose escalation planning
Evaluate emergency kit readiness and caregiver education
Monitor medication continuity and refill vulnerability
Address environmental and heat-related destabilization risk
ACDF-Core™: Adrenal Crisis Decision Framework
Embedded within CDF-Adrenal™ is ACDF-Core™, a crisis-oriented operational framework designed to support rapid escalation, assay-aware interpretation, and physiologic stabilization during suspected adrenal deterioration.
Lane A: Adrenal Insufficiency Risk Identification
This intake layer identifies patients who should trigger adrenal instability evaluation based on symptom clusters, contextual risk factors, and physiologic vulnerability.
Risk amplifiers include:
recent glucocorticoid withdrawal
chronic corticosteroid exposure
physiologic stress while steroid-dependent
pituitary or hypothalamic disease
autoimmune disease
medication-induced cortisol suppression
recurrent orthostatic or electrolyte instability
Importantly, NICE guidance notes that hyperpigmentation may present differently across skin tones and recommends evaluating patient reported skin tone changes as well as buccal mucosa and scars rather than relying solely on visual assumptions in darker skin (NICE, 2024).
Lane B: Assay-Aware Cortisol Interpretation
CDF-Adrenal™ treats assay context as mandatory metadata rather than optional context.
All cortisol values should include:
specimen type
assay platform
immunoassay generation or LC-MS/MS status
timing of collection
local threshold applicability
This prevents inappropriate portability of thresholds across incompatible methodologies and reduces false reassurance around borderline values.
Lane C: Crisis Override and Emergency Stabilization
When adrenal crisis is suspected, stabilization overrides diagnostic ambiguity. NICE guidance recommends immediate hydrocortisone administration during suspected adrenal crisis and explicitly states that there is no overdose risk in emergency treatment contexts (NICE, 2024). Crisis management also includes rapid isotonic saline administration and escalation to parenteral therapy when oral absorption becomes unreliable. CDF-Adrenal™ therefore models crisis not as a binary event, but as a progressive loss of adaptive buffering capacity.
Patient-Centered Outcomes and Adaptive Labor
Traditional endocrine outcome frameworks primarily capture biochemical adequacy and hospital-level events. However, much of the real burden of adrenal insufficiency exists in the space between apparent stability and overt crisis.
Patients frequently prevent deterioration through continuous adaptive labor, including:
preemptive stress dosing
environmental control
activity modification
medication rationing decisions
travel planning
hydration management
monitoring for early physiologic decline
caregiver coordination
These efforts are rarely captured in conventional research frameworks despite profoundly shaping quality of life and crisis prevention.
CDF-Adrenal™ therefore incorporates patient centered outcomes including:
near-miss crisis events
decision confidence
caregiver vigilance burden
medication continuity stability
time-to-recovery after physiologic stressors
orthostatic symptom volatility
emergency kit readiness
functional predictability and ability to safely leave home
This framework recognizes that reduced uncertainty and improved physiologic safety may represent clinically meaningful improvements even in the absence of complete symptom resolution.
Assay Variability and Measurement Integrity
A core principle of CDF-Adrenal™ is that cortisol values cannot be interpreted independently from assay methodology. Research demonstrates substantial variability across immunoassays and LC-MS/MS platforms due to calibration differences, cross reactivity, specimen effects, and methodological limitations (Miller et al., 2013; Noel et al., 2022; Antonelli et al., 2023).
Accordingly, the framework includes an Assay Tag requirement: Every cortisol value incorporated into CDF-Adrenal™ must retain associated assay metadata to preserve interpretive integrity and reduce inappropriate threshold generalization. This systems based approach improves cross-site comparability, longitudinal monitoring reliability, and clinical safety.
Steroid Exposure Attribution Guardrail
Patients with MCAS, dysautonomia, autoimmune disease, Long COVID, ME/CFS, and related infection-associated chronic conditions may have corticosteroid exposure documented in the electronic health record without adequate contextual interpretation regarding dose, duration, indication, prior tolerability, taper history, or baseline symptom patterns before steroid use. In acute care settings, this can contribute to attribution bias, where complex multisystem symptoms are incorrectly assigned to corticosteroid exposure while underlying inflammatory, autonomic, endocrine, mast cell, or infection associated instability remains under-evaluated (Bornstein et al., 2016; Afrin, 2016; Sheldon et al., 2015; Komaroff and Bateman, 2021; Davis et al., 2023).
This issue is particularly important because corticosteroids are commonly prescribed across these populations for asthma, allergic reactions, autoimmune flares, inflammatory conditions, mast cell stabilization attempts, respiratory symptoms, and emergency symptom control. Long term or repeated glucocorticoid exposure can suppress hypothalamic pituitary adrenal axis function, while abrupt withdrawal, dose reduction, or physiologic stress during suppression can increase adrenal insufficiency risk (Broersen et al., 2015; Bornstein et al., 2016; Prete and Bancos, 2021; NICE, 2024). Clinical references also note that adrenal insufficiency may remain masked until illness or stress triggers adrenal crisis.
CDF-Adrenal™ therefore treats steroid exposure as a contextual modifier rather than an automatic causal explanation. The framework requires evaluation of corticosteroid dose and duration, taper timing, withdrawal history, prior symptom patterns before steroid exposure, comparative symptom severity on versus off corticosteroids, prior emergency presentations unrelated to steroid use, stress response deterioration patterns, evidence of adrenal suppression risk, and concurrent autonomic, inflammatory, mast cell, or infection associated instability.
This approach reduces the risk of both under-recognizing steroid-induced adrenal suppression and over-attributing unrelated physiologic instability to corticosteroid exposure alone. The framework further recognizes that fragmented documentation across specialties may obscure longitudinal clinical reasoning, particularly for patients with medically complex, poorly understood, or historically dismissed multisystem conditions (Epstein et al., 2010; Safford et al., 2012; Verghese et al., 2018). Patients frequently move between providers, emergency departments, and specialty systems where prior stabilization decisions, risk-benefit tradeoffs, and individualized dosing rationale may not remain visible within the EHR. Context aware interpretation is therefore essential for safe endocrine and crisis-risk assessment.
Steroid Response Variability as a Systems Signal
Infection associated chronic conditions, dysautonomia, MCAS, autoimmune disease, and related multisystem inflammatory disorders frequently demonstrate substantial variability in corticosteroid response patterns. Some patients experience marked improvement in inflammation, allergic reactivity, orthostatic symptoms, pain, respiratory symptoms, or functional capacity during corticosteroid exposure, while others experience worsening autonomic instability, tachycardia, neuropsychiatric activation, rebound inflammation, insomnia, blood pressure dysregulation, or delayed post-exposure crashes (Theoharides et al., 2015; Afrin, 2016; Sheldon et al., 2015; Komaroff and Bateman, 2021; Proal and VanElzakker, 2021).
These patterns are widely discussed across patient communities yet remain insufficiently characterized within formal endocrine and chronic illness literature. Importantly, variable corticosteroid response should not automatically be interpreted as evidence of adrenal insufficiency. However, these response patterns may reflect overlapping dysfunction involving autonomic regulation, inflammatory signaling, HPA-axis suppression risk, mast cell activation, glucocorticoid sensitivity variation, circadian instability, and impaired adaptive physiologic reserve (Chrousos, 2009; Charmandari et al., 2014; Sapolsky et al., 2000; Bornstein et al., 2016).
CDF-Adrenal™ therefore incorporates steroid response history as a systems level contextual signal rather than a binary indicator of benefit or harm. The framework distinguishes between confirmed adrenal insufficiency, steroid induced adrenal suppression risk, glucocorticoid sensitivity or intolerance, rebound inflammatory instability, autonomic destabilization during steroid exposure or withdrawal, and broader adaptive buffering dysfunction. This distinction is important because many patients with multisystem chronic illness occupy physiologic gray zones that are not fully captured by traditional endocrine threshold models. Patients may demonstrate impaired stress tolerance, fluctuating autonomic compensation, circadian disruption, inflammatory volatility, and disproportionate physiologic responses to environmental or physiologic stressors without meeting formal criteria for primary adrenal insufficiency (Institute of Medicine, 2015; Proal and VanElzakker, 2021; Davis et al., 2023).
Within CDF-Adrenal™, these overlapping patterns are interpreted as indicators of adaptive stress-response instability rather than assumptions of isolated adrenal cortex pathology. This systems based approach supports more nuanced interpretation of corticosteroid response patterns while avoiding both premature endocrine labeling and dismissal of clinically meaningful physiologic instability.
Conclusion: Toward Earlier Recognition and Physiologic Stability
Adrenal insufficiency is not difficult to recognize because it lacks measurable biology, but because its instability unfolds dynamically across physiologic systems, environmental stressors, and real world management burdens that traditional frameworks often fail to integrate early.
CDF-Adrenal™ reframes adrenal insufficiency as a distributed adaptive buffering disorder rather than a static hormone deficiency state. By organizing endocrine signaling, electrolyte regulation, autonomic compensation, crisis vulnerability, medication continuity, and structural burden into a unified composite diagnostic architecture, the framework enables earlier recognition, more context-aware interpretation, and more consistent stabilization planning.
This approach aligns with a broader shift toward understanding chronic illness as a dynamic systems state where stability, resilience, crisis prevention, and functional predictability are as clinically meaningful as isolated laboratory thresholds. Within CYNAERA, this framework also supports future integration with adaptive monitoring systems, longitudinal flare prediction models, environmental risk overlays, and patient centered comparative effectiveness research focused on reducing physiologic uncertainty and improving long term safety.
How to Cite This Paper
Adinig, C. (2026). CDF-Adrenal™: A Composite Diagnostic Fingerprint for Adrenal Insufficiency. CYNAERA. Available at: https://www.cynaera.com/post/cdf-adrenal
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Afrin, L.B. (2016). Never Bet Against Occam: Mast Cell Activation Disease and the Modern Epidemics of Chronic Illness and Medical Complexity. Sisters Media.
Antonelli, G., Ceccato, F., Artusi, C., Marinova, M., Plebani, M. and Boscaro, M. (2015). Salivary cortisol and cortisone by LC-MS/MS: validation, reference intervals and diagnostic accuracy in Cushing’s syndrome. Clinical Chimica Acta, 451, pp.247–251.
Bancos, I., Hahner, S., Tomlinson, J. and Arlt, W. (2015). Diagnosis and management of adrenal insufficiency. The Lancet Diabetes & Endocrinology, 3(3), pp.216–226.
Bornstein, S.R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G.D., Husebye, E.S., Merke, D.P., Murad, M.H., Stratakis, C.A. and Torpy, D.J. (2016). Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 101(2), pp.364–389.
Broersen, L.H.A., Pereira, A.M., Jørgensen, J.O.L. and Dekkers, O.M. (2015). Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 100(6), pp.2171–2180.
Charmandari, E., Nicolaides, N.C. and Chrousos, G.P. (2014). Adrenal insufficiency. The Lancet, 383(9935), pp.2152–2167.
Chrousos, G.P. (2009). Stress and disorders of the stress system. Nature Reviews Endocrinology, 5(7), pp.374–381.
Dalakas, K., Allosso, F., Basile, C., Bergthorsdottir, R., Chantzichristos, D., Hessman, E., Nwaru, B.I., Bobbio, E., Pasquali, D., Johannsson, G. and Esposito, D. (2025). Increased mortality in primary adrenal insufficiency: a systematic review and meta-analysis. European Journal of Endocrinology, 193(4), pp.S53–S60.
Davis, H.E., McCorkell, L., Vogel, J.M. and Topol, E.J. (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21, pp.133–146.
Institute of Medicine. (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press.
Miller, R., Plessow, F., Rauh, M., Gröschl, M. and Kirschbaum, C. (2013). Comparison of salivary cortisol as measured by different immunoassays and tandem mass spectrometry. Psychoneuroendocrinology, 38(1), pp.50–57.
NICE. (2024). Adrenal insufficiency: identification and management. NICE Guideline NG243. National Institute for Health and Care Excellence.
Noel, M.M., Blondeau, B., Clerc, D., Claustrat, B., Raverot, G. and Borson-Chazot, F. (2022). Novel threshold value of midnight serum cortisol for diagnosis of hypercortisolism using the Roche Cortisol II assay. Clinical Biochemistry, 99, pp.66–70.
Prete, A. and Bancos, I. (2021). Glucocorticoid induced adrenal insufficiency. BMJ, 374, n1380.
Proal, A.D. and VanElzakker, M.B. (2021). Long COVID or post-acute sequelae of COVID-19: an overview of biological factors that may contribute to persistent symptoms. Frontiers in Microbiology, 12, 698169.
Rushworth, R.L., Torpy, D.J. and Falhammar, H. (2019). Adrenal crisis. The New England Journal of Medicine, 381(9), pp.852–861.
Sheldon, R.S., Grubb, B.P., Olshansky, B., Shen, W.K., Calkins, H., Brignole, M., Raj, S.R., Krahn, A.D., Morillo, C.A., Stewart, J.M., Sutton, R., Sandroni, P., Friday, K.J., Hachul, D.T., Cohen, M.I., Lau, D.H., Mayuga, K.A., Moak, J.P., Sandhu, R.K. and Kanjwal, K. (2015). 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm, 12(6), pp.e41–e63.
Theoharides, T.C., Valent, P. and Akin, C. (2015). Mast cells, mastocytosis, and related disorders. The New England Journal of Medicine, 373(2), pp.163–172.
Comments